Full text is available at the source.
Abstract
A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy after acute ischemic stroke or high-risk transient ischemic attack.
- The role of GLP-1RA therapy in the early treatment of acute ischemic stroke or high-risk transient ischemic attack is currently uncertain.
- Existing randomized evidence related to the use of GLP-1RA in this context was systematically reviewed.
- Both efficacy and safety outcomes of GLP-1RA therapy in patients post-stroke were assessed.
Simplified